San Diego-based GlySens Inc. announced that it has been awarded a two-year, $2 million dollar grant from the National Institute of Diabetes and Digestive and Kidney Diseases, a division of the National Institutes of Health (NIH).
The company said the funding is intended to support human clinical evaluation of the GlySens second generation ICGM long term implantable glucose monitoring system. Final preparations for launch of the trial are underway, and enrollment is expected to begin before the end of 2014.
"We are extremely pleased and grateful to have the support of NIDDK and the NIH as we take these next steps in the development of the GlySens ICGM system," said Joseph Lucisano, GlySens president and CEO. "As appreciation continues to grow for the potential of continuous glucose monitoring to make a real difference in the lives of people with diabetes, the need to provide an effective, widely acceptable, patient-friendly product has never been greater. We believe that our long term system approach, with its fully implantable sensor intended to operate continuously for one year without need for replacement, will provide the convenience and ease of use that patients desire and foster widespread application of continuous glucose monitoring in diabetes care.”
“The long-standing engagement of the NIH with our research program has provided tremendous value in helping us ensure that our approach aims to serve a broad range of patient needs while we also maintain the highest level of scientific rigor in our efforts,” he added. “We look forward to conducting this upcoming clinical trial with NIH support."